spacer
home > ebr > autumn 2017 > driving discovery
PUBLICATIONS
European Biopharmaceutical Review

Driving Discovery

Cytochromes P450 (P450s) are a superfamily of enzymes present in all organisms. They contain a haem moiety that forms the catalytic centre and primarily function as monooxygenases, adding an oxygen to their substrates (see Figure 1) (1). P450s are highly relevant in drug discovery because they are responsible for Phase 1 metabolism of approximately 70-80% of drugs (2). Several P450 isoforms contribute to human drug metabolism; the most important of these are summarised in Figure 2. Many issues affecting potential drugs can arise from P450 metabolism:

  • Rapid metabolism can lead to poor bioavailability or rapid clearance, resulting in low exposure and efficacy
  • Co-administration of drugs can cause drug-drug interactions (DDIs), whereby inhibition or induction of a P450 isoform by one therapeutic can dramatically affect the metabolism of another, causing significant changes in exposure
  • Genetic polymorphisms in patient populations affect the rates of metabolism by major P450 isoforms, including CYP2D6 and CYP2C19, generating large variabilities in exposure between patients
  • Metabolism by P450s can lead to bioactivation of compounds and the formation of reactive or toxic metabolites

In an effort to reduce these issues, in vitro assays of P450 metabolism-related properties are widely used in the drug discovery process (3). High-throughput assays, such as measurement of turnover in human liver microsomes or inhibition of P450 isoforms, are applied as early screens. However, more detailed studies, such as metabolite identification, remain expensive and time-consuming, hence they are typically applied later in the process to a limited number of compounds.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthew Segall has an MSc in computation from the University of Oxford, UK, and a PhD in theoretical physics from the University of Cambridge, UK. At Camitro, ArQule and Inpharmatica, he led a team developing predictive absorption, distribution, metabolism and excretion (ADME) models and intuitive decision-support tools for drug discovery. In 2006, Matt became responsible for management of Inpharmatica's ADME business and, following acquisition of Inpharmatica, he took up the role of Senior Director of BioFocus DPI's ADMET division. In 2009, he led a management buyout of the StarDrop business to found Optibrium Ltd, which develops software for small molecule design, optimisation and data analysis.
spacer
Matthew Segall
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kindeva Drug Delivery, Formerly 3M Drug Delivery Systems, Launches as an Independent Company

Kindeva is a leading global contract development and manufacturing organization (CDMO) that specializes in solving complex drug delivery challenges for its pharmaceutical and biotechnology customers. With approximately 900 employees, Kindeva serves customers with a wealth of expertise in formulation, product development and manufacturing. Kindeva-developed and manufactured therapies treat patients battling a host of debilitating and chronic diseases, including respiratory illnesses and cardiovascular conditions. The company's microneedle-based drug delivery platforms are currently being utilized in dozens of development programs, including programs for osteoporosis, immunotherapies, COVID-19 vaccines, and other difficult-to-deliver therapies.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein´┐Żs primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement